8,143 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Genmab's pain is Verastem's gain, up 5% https://seekingalpha.com/news/3359376-genmabs-pain-verastems-gain-5-percent?source=feed_news_all May 24, 2018 - Verastem (VSTM +5.1%) is up on average volume in apparent response to Genmab's (OTCPK:GNMSF)(OTCPK:GMXAY) failed late-stage study of Arzerra (ofatumumab) in indolent B-cell non-Hodgkin lymphoma. Ofatu
Story Stocks: Goldman & JP Morgan Led Kiniksa Pharmaceuticals Prices Up-Sized IPO at Midpoint (KNSA) http://www.briefing.com/investor/popuppages/articlepopup.aspx?articleId=NS20180524092323StoryStocks May 24, 2018 - Pharmaceutical IPO, Kiniksa Pharmaceuticals (KNSA), priced this morning at $18. The company is a cl
Bernstein: Amazon Flex Is No Threat To FedEx, UPS http://feeds.benzinga.com/~r/benzinga/~3/g7AVE699AEo/bernstein-amazon-flex-is-no-threat-to-fedex-ups May 24, 2018 -

Amazon.com, Inc. (NASDAQ: AMZN) investors are always on the lookout for the company’s next disruptive business, and some believe it could be parcel delivery.

Idera to collaborate with Bristol-Myers on study of IMO-2125/Yervoy combo in melanoma; shares up 4% premarket https://seekingalpha.com/news/3359282-idera-collaborate-bristol-myers-study-imominus-2125-yervoy-combo-melanoma-shares-4-percent?source=feed_news_all May 24, 2018 - Idera Pharmaceuticals (NASDAQ:IDRA) is up 4% premarket on light volume on the heels of its announced clinical trial collaboration and supply agreement with Bristol-Myers Squibb (NYSE:BMY) re
Daily Insider Ratings Round Up 5/22/18 https://seekingalpha.com/article/4176800-daily-insider-ratings-round-5-22-18?source=feed_all_articles May 24, 2018 - Tables of the top insider purchases and sales filed with the SEC on 5/22/18, based on dollar value. Dollar values often do not equate with significance when it comes to insider trades. Proprietary Ins
FDA accepts AcelRx's Dsuvia NDA, shares up 13% premarket https://seekingalpha.com/news/3359241-fda-accepts-acelrxs-dsuvia-nda-shares-13-percent-premarket?source=feed_news_all May 24, 2018 - AcelRx Pharmaceuticals (NASDAQ:ACRX) is up 13% premarket on average volume in response to its announcement that the FDA has accepted for review its marketing application seeking approval for
Celgene to buy back additional $3B of stock; shares up 1% premarket https://seekingalpha.com/news/3359238-celgene-buy-back-additional-3b-stock-shares-1-percent-premarket?source=feed_news_all May 24, 2018 - The board of Celgene (NASDAQ:CELG) has authorized the repurchase of an additional $3B of its common stock and the accelerated repurchase of $2B of stock. The accelerated buybacks will use part of the
Ex-Sabres owner Golisano has had it up to here with NY property taxes, goose poop http://feeds.bizjournals.com/~r/industry_21/~3/8JdHJPT28Ms/ex-sabres-owner-golisano-has-had-it-up-to-here.html May 24, 2018 - Certainly, you remember B. Thomas Golisano. Perhaps as the businessman who became a billionaire after launching Paychex Inc. in Rochester. Or as a three-time candidate for governor of New York state. Or as the former owner of the Buffalo Sabres, which he sold to Terry and Kim Pegula in 2011. Or as a benefactor to Niagara University and Niagara Falls Memorial Medical Center. Now 76, Golisano is embroiled in a high-stakes dispute with assessors over his property tax bill on his Canandaigua Lake…
Danish hearing-aid giant ramps up growth in Bloomington http://feeds.bizjournals.com/~r/industry_6/~3/qlGR5CD1-Nk/danish-hearing-aid-giant-ramps-up-growth-in.html May 24, 2018 - GN Hearing added hundreds of employees to its Twin Cities in recent years under the leadership of Kim Lody.
Editorial: Is Paul McKee's time up? http://feeds.bizjournals.com/~r/industry_20/~3/SSMeQzdqCCI/editorial-is-paul-mckees-time-up.html May 24, 2018 - Mayor Lyda Krewson’s administration should act swiftly to find the NorthSide Regeneration developer in default.

Pages: 12345678910...815

<<<Page 5>